# Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.

> **NCT03069170** · PHASE1 · UNKNOWN · sponsor: **Stem Cells Arabia** · enrollment: 50 (estimated)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** Stem Cell Transplantation

## Key facts

- **NCT ID:** NCT03069170
- **Lead sponsor:** Stem Cells Arabia
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07
- **Primary completion:** 2020-09
- **Final completion:** 2021-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03069170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03069170, "Autologous Bone Marrow Derived Stem Cells for the Treatment of Multiple Sclerosis.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03069170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*